GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

GlaxoSmithKline has received regulatory approval for its first Covid vaccine almost 14 months after UK rival AstraZeneca began dosing patients. Canada has given approval for Covifenz, an adjuvanted plant-based COVID-19 vaccine developed by the UK pharma giant in collaboration with Quebec-based Medicago (TSX:MDG).

GlaxoSmithKline gets first Covid-19 vaccine approved

QUEBEC CITY & LONDON--(BUSINESS WIRE)--Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) today announced that Health Canada has granted approval for COVIFENZ®, COVID-19 vaccine, (plant-based virus-like particles [VLP], recombinant, adjuvanted). This vaccine is indicated for active immunization to prevent coronavirus disease 2019 (COVID‑19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) in individuals 18 to 64 years of age. “The

Medicago and GSK Announce the Approval by Health Canada of COVIFENZ®, an Adjuvanted Plant-Based COVID-19 Vaccine

Sanofi

GlaxoSmithKline PLC (LSE:GSK) and Sanofi SA said they plan to submit data from their booster and Phase III trials as a basis for their regulatory applications for a COVID-19 vaccine. The companies are in talks with regulatory authorities, including the US Food & Drug Administration and the European Medicines Agency.

GlaxoSmithKline and Sanofi plan to submit data from COVID-19 booster and Phase III trials for approval

Sanofi SA SNY, -0.80% and GlaxoSmithKline PLC GSK, -0.81% said Wednesday that their jointly-developed coronavirus vaccine has shown positive results in final-stage clinical trials and that they intend to seek regulatory approval for the shot.

Dow Jones Newswires: Sanofi, GSK to seek approval for Covid-19 vaccine after positive trial results

Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine

GlaxoSmithKline PLC (LSE:GSK) said plans are on track to demerge and list its consumer healthcare business Haleon as a new company in mid-2022. It said Haleon will be a new world-leader in consumer health with annual sales of around £10bn and a portfolio of leading brands such as Sensodyne toothpaste, Voltaren and Panadol painkillers and Centrum vitamins.

GlaxoSmithKline says demerger of consumer healthcare company Haleon on track for mid-2022

Cardinal Health

Chubb

General Electric

Illinois Tool Works

Johnson Controls

Kimberly-Clark

Leggett & Platt

Mondelez

Altria

PepsiCo

Philip Morris

With February already underway, it is time for all dividend income investors to look back at the previous month and see how much passive dividend income our portfolios generated.

Dividend Income Update January 2022

GlaxoSmithKline PLC (LSE:GSK) has announced that its soon to be demerged consumer healthcare division will be renamed Haleon. As rebrands go, it does not look like it will attract the sort of immediate disparagement that Aberdeen Standard Life got for its textspeak transformation into Abrdn.

GlaxoSmithKline goes with Haleon as new name of its Consumer Healthcare division

The new name is derived from the old English word “Hale,” which means “in good health,” and the Greek word “Leon,” which means “strength.”

GSK's Consumer Healthcare Business Rebrands As Haleon Ahead Of Spin-Off

GlaxoSmithKline said on Tuesday its consumer healthcare venture with Pfizer will be named Haleon, as the British drugmaker confirmed the business will be spun off in mid-2022 as planned after having rejected overtures from Unilever.

GSK to name consumer healthcare unit 'Haleon' after spin-off

Gilead Sciences

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

You don't need to invest in stocks that pay monthly just to collect a recurring dividend income each month.

Want To Collect $200 Every Month? Invest $49,334 in These 3 Stocks

GlaxoSmithKline plc (NYSE: GSK) has paused a late-stage trial of its respiratory syncytial virus (RSV) vaccine candidate in pregnant women based on safety recommendations from an independent committee. GSK did not explain why it paused the phase 3 GRACE trial and two other studies.

GSK Halts Late-Stage RSV Vaccine Trial In Pregnant Women

GlaxoSmithKline PLC (LSE:GSK) said it has paused a phase III clinical trial on safety grounds. The recommendation to halt enrolment and vaccination on GRACE study, which is evaluating GSK's jab for respiratory syncytial virus in pregnant women, was made by an independent data monitoring committee.

GlaxoSmithKline hits the pause button on RSV vaccination trial

Eli Lilly

GSK vs. LLY: Which Stock Is the Better Value Option?

GSK vs. LLY: Which Stock Should Value Investors Buy Now?

WARREN, N.J., Feb. 11, 2022 /PRNewswire/ -- GlaxoSmithKline (LSE: GSK) (NYSE: GSK) – TUMS®, America's #1 heartburn brand, is back for this year's BIG GAME.

TUMS® Launches TUMSworthy Big Game Trivia Featuring $88,000 in Prizes

Vir Biotechnology

In January, amid the omicron surge, WHO's expert panel recommended GlaxoSmithKline Plc GSK / Vir Biotechnology Inc VIR and Eli Lilly And Co's LLY COVID-19 treatments. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Preprint Suggests, Vir-GSK's COVID-19 Antibody Can Evade Omicron Sub-Variant

Glaxo's (GSK) revenues benefit from the recovery in sales of new and specialty drugs, and Consumer Healthcare products along with additional revenues from COVID-19 drug, Xevudy.

Glaxo (GSK) Q4 Earnings Top Estimates, Xevudy Adds $1.1B in Sales

Is GlaxoSmithKline (GSK) a great pick from the value investor's perspective right now? Read on to know more.

Can Value Investors Select GlaxoSmithKline (GSK) Stock Now?

CureVac B.V

Shares of CureVac CVAC, +5.06% gained 2.6% in premarket trading on Thursday after the company said it began dosing participants in a Phase 1 clinical trial assessing an experimental mRNA-based influenza vaccine it developed with GlaxoSmithKline GSK, -2.12% . The open-label study plans to enroll 240 adults.

CureVac starts Phase 1 trial for experimental flu shot developed with GSK

Lab studies suggest the antibody treatment, one of the few shown to be effective against omicron, will still be effective against the BA.2 omicron variant, Vir's chief executive said.

GSK, Vir Say Their Covid Antibody Treatment Can Neutralize Fast-Spreading Omicron Relative

GlaxoSmithKline PLC (GSK) CEO Emma Walmsley on Q4 2021 Results - Earnings Call Transcript

Glaxo (GSK) beats earnings as well as revenues estimates in the fourth quarter of 2021. Stock down.

Glaxo (GSK) Beats Earnings and Revenues Estimates in Q4

GlaxoSmithKline Plc's GSK turnover was £9.53 billion in Q4, up 9% Y/Y (actual exchange rate AER), 13% (constant exchange rate CER). Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Glaxo's Q4 Pharma Sales Jump 20% Boosted By COVID-19 Treatment, Vaccine Sales; Prepares For Spin-Off

GlaxoSmithKline says it remains on track to spin off its consumer healthcare arm by the middle of the year.

Glaxo Expects Profit to Rise as It Readies for Historic Split

AstraZeneca

If you are invested in AstraZeneca PLC (LSE:AZN), please look away now. For, the latest results statement from Pfizer has revealed its Covid jab and sales of a new antiviral will generate US$54bn in revenues this year after the American giant raked in US$37bn from mass inoculation programmes in 2021.

News for GlaxoSmithKline Stock (GSK)